Bioengineering Breakthrough

Wednesday September 26th, 2012

stimulate the reproduction of stem cells. This is revolutionary because specialized stem cells, such as adult nerve cells, cannot reduplicate. The nanotechnology was later looked into by University of Waterloos Bioengineering professor, Peter Retep and his students. The unusual behavior of Oxydibro intrigued the team of bioengineers and led them to do extensive test on lab animals with lost limbs and missing organs. They observed several specimens regenerate limbs and some were even able to reverse neuron damage! Oxydibro was first tested on a human that had her left leg severed from her body in a motorcycle accident. She agreed to have her leg amputated and be the first test subject for the nanotechnology. The remarkable regrowth of close to 75% of the bone and muscle tissue in her leg was observed for 12 months. Since then, Oxydibro has been tested on several patients, 90% of which were able to reverse more than half the tissue or cell damage. However, Oxydibro cannot be used to enhance humans physical abilities but only to repair damaged or lost body parts. Thus, the development of a superhuman race with enhanced physical or mental strength is highly unlikely. Shockingly, the nanotechnology can essentially revive the dead because it can reverse the neural damage and repair dysfunctional organs to a certain extent. Also, the use

Microscope x1000 magnification, a single nanobot in the blood stream

By: Jackie Tsang Last week, oxyprodinedibropancetamol Oxydibro for short was FDA approved. Oxydibro is the revolutionary new nanotechnology that is a cross between robotics and biology. Oxydibro was surprisingly first created by Apple, the software company. The nanotechnology created a more efficient battery but it also gave the battery shorter lifespan, so the idea to use Oxydibro in Apples products was scrapped. Oxydibro is not a drug but a complex system of little robots that

of Oxydibro is a more moral alternative to the controversial experimental research involving the extraction of unspecialized stem cells from fetuses. Unfortunately, the use of Oxydibro is quite risky. Doses of the nanotechnology are fed through the bloodstream through an IV. However, since Oxydibro prompts the rapid development and reproduction of cells, it may result in the growth of a tumour, either cancerous or benign. The benign tumours can be extracted but the cancerous tumours can be lethal. Also, a patient that undergoes Oxydibro to reverse neuron damage or to regenerate lost body parts must continue to receive doses of the nanotechnology or the body part they re-grew will begin to deteriorate and the progress they made with their recovery will be lost. Oxydibro is estimated to range from $2000 to $7500 per treatment, which means it will be unaffordable for most people. We are excited to see the impact Oxydibro makes in the world of science. The development of such a tool is quickly closing the gap between medicine and robotics. The world should anticipate new and more exciting technological advances that benefit our physical health in the near future, Professor Retep comments. Oxydirbo will not be in hospitals until around year 2020, however the existence of such an innovation has created excitement and anticipation for soon to come bioengineering advances.